) recently announced that the company obtained CE Marking
(Conformite Europeenne) for its ARCHITECT Galectin-3 assay
We note that CE mark is mandatory confirmation for products
placed in the European markets. Abbott developed this test in
BG Medicine, Inc.
) to run on the ARCHITECT immunochemistry platform of
The test is primarily aimed to enable doctors in assessing the
prognosis of patients diagnosed with chronic heart failure (HF).
ARCHITECT Galectin-3 assay test is available in several European
Galectin-3 can indicate heart failure by chalking out the
pathophysiology of heart failure. Subsequently, the doctors
can identify susceptible patients for heart failure who are at
Abbott continues to focus on the development of
next-generation instruments and other advanced technologies along
with expansion in emerging markets in its diagnostics
Abbott looks to improve operating margins in this segment. In
2012, the company took steps to streamline various commercial
operations in order to reduce costs and thereby improve
Meanwhile, Abbott is working on boosting its vascular products
portfolio and expects to launch several products in the next five
The company intends to work on increasing international
MitraClip sales and developing ABSORB, its bioresorbable vascular
scaffold (BVS) device.
Abbott is also focusing on strengthening its drug eluting
product portfolio, powered by the launch of Xience Xpedition
drug-eluting stent in Europe in Aug 2012 and in the US in Jan
2013. Abbott expects to launch Xpedition in Japan in mid-2013 and
market products in the Xience family.
We believe that Abbott is extremely diversified with
businesses in nutrition, diagnostics, generic pharmaceuticals and
medical devices after spinning off its pharmaceuticals business
into a separate company,
Abbott currently carries a Zacks Rank #3 (Hold). Right now,
) looks better placed in the medical devices sector with a Zacks
Rank #1 (Buy).
ABBVIE INC (ABBV): Free Stock Analysis Report
ABBOTT LABS (ABT): Free Stock Analysis Report
BG MEDICINE INC (BGMD): Free Stock Analysis
NUVASIVE INC (NUVA): Free Stock Analysis
To read this article on Zacks.com click here.